Clinical Trials on Intrapartum - Moderate and Severe Anaemia

Total 8074 results

London School of Hygiene and Tropical Medicine
Bill and Melinda Gates Foundation; Wellcome Trust

Completed

World Maternal Antifibrinolytic Trial_2 (WOMAN-2)

Intrapartum - Moderate and Severe Anaemia

Nigeria, Pakistan, Tanzania, Zambia
University of Utah
Novartis

Completed

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

Severe Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic Anemia

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Up-front Matched Unrelated Donor Transplantation in Pediatric Patients With Idiopathic Aplastic Anemia (UPFRONT-MUD)

Severe Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
Prof Kathryn Maitland
Imperial College London

Completed

Study of Safe Blood Transfusion Volumes to Correct Acute Severe Anaemia (Tx30)

Severe Anaemia

Uganda
Beer, Kenneth R., M.D., PA
Medicis Pharmaceutical Corporation

Completed

Upper Facial Remodeling With Perlane-L and Dysport (DPL-2010)

Mild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital Rhytids

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

Moderate-severe Glabellar Lines
Aqpha Medical B.V.

Not yet recruiting

Safety and Performance of PTMC Dermal Filler

Moderate to Severe Nasolabial Fold
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Allergan

Completed

Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

Moderate to Severe Nasolabial Folds

Germany, Netherlands
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Anti-age Food Supplement

Moderate-severe Skin Aging/Photoaging
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Belgium, France, Germany, Italy, Spain, United Kingdom
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Kythera Biopharmaceuticals
Bayer

Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Germany, France, Belgium, Spain, United Kingdom
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
AbbVie

Completed

Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Japan
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Croma-Pharma GmbH

Completed

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Moderate to Severe Nasolabial Folds

Austria
Allergan

Completed

A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Moderate to Severe Nasolabial Folds

United States
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
Merz North America, Inc.

Completed

Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit

Moderate to Severe Midface Volume Deficit

Canada
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Merz Aesthetics GmbH
Merz Pharmaceuticals GmbH

Completed

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States, Germany
Croma-Pharma GmbH

Active, not recruiting

Saypha® VOLUME Lidocaine for Midface Augmentation (VOLIDO)

Moderate to Severe Midface Volume Deficit

United States
Allergan

Completed

JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines

Patients With Moderate to Severe Perioral Lines

United States
Al-Azhar University

Enrolling by invitation

Evaluation of Effects of Bracket's Slot System on the Quantity and Quality of Teeth Movements During Orthodontic Leveling and Alignment Stage

Moderate and Severe Crowding in Lower Dental Arch

Egypt
Sandoz

Completed

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Mild and Moderate Iron-deficiency Anaemia

Russian Federation
Xinhua Hospital, Shanghai Jiao Tong University...

Terminated

Explore Efficacy of FMT Treating Childhood ASD Patients

ASD Accompanied by Moderate to Severe Gastrointestinal Symptoms

China
Merz North America, Inc.

Completed

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Moderate to Severe Nasolabial Folds

Correction of Moderate to Severe Nasolabial Folds (NLFs)

China
Merz North America, Inc.

Completed

Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds in China

Correction of the Moderate to Severe Nasolabial Folds

China
Pfizer

Terminated

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

Moderate-severe Pain

United States
Astellas Pharma Europe Ltd.

Completed

A Survey About Trade-offs When Choosing Menopause Treatments

Moderate to Severe Vasomotor Symptoms

United Kingdom
Pfizer

Terminated

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Moderate-severe Pain

United States
LG Life Sciences

Unknown

Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar Region

Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region

Korea, Republic of
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Kythera Biopharmaceuticals

Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China

Clinical Trials on Intrapartum - Moderate and Severe Anaemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations